BeiGene Switches To Combo Therapy Approach For Brukinsa

 
• By Dexter Jie Yan

BeiGene exec reveals Chinese firm's changing development strategy around key asset as further clinical results emerge.

BeiGene is ending Brukinsa's head-to-head clinical studies versus Imbruvica.
BeiGene ending Brukinsa's head-to-head studies versus Imbruvica • Source: Alamy

More from China

More from Focus On Asia